# Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

> **NCT02464605** · PHASE1 · COMPLETED · sponsor: **Selecta Biosciences, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Gout

## Interventions

- **BIOLOGICAL:** SEL-037 (pegsiticase)

## Key facts

- **NCT ID:** NCT02464605
- **Lead sponsor:** Selecta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-11
- **Final completion:** 2016-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464605, "Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02464605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*